FDA Says Nasal Spray Flu Vaccine Needs No Additional Clinical Trials
- Date:
- July 15, 2002
- Source:
- University Of Michigan
- Summary:
- The U.S. Food and Drug Administration has asked for additional information, but no additional clinical trials, as it considers approval of FluMist, an influenza vaccine delivered as a nasal spray. FluMist was invented by Hunein “John” Maassab after more than four decades of research at the University of Michigan School of Public Health. Gaithersburg, Md.-based MedImmune has licensed the rights to FluMist from U-M, and has a marketing agreement with pharmaceutical giant Wyeth.
- Share:
ANN ARBOR – The U.S. Food and Drug Administration has asked for additional information, but no additional clinical trials, as it considers approval of FluMist, an influenza vaccine delivered as a nasal spray.
FluMist was invented by Hunein “John” Maassab after more than four decades of research at the University of Michigan School of Public Health. Gaithersburg, Md.-based MedImmune has licensed the rights to FluMist from U-M, and has a marketing agreement with pharmaceutical giant Wyeth.
“I am pleased that the FDA does not believe that additional clinical trials are necessary. The efficacy of FluMist is clearly established. I expect that MedImmune will be able to respond to any FDA questions. I am happy to see this progress," Maassab said today (July 11). Maassab is on medical leave from U-M and is unavailable for media interviews. Rosemary Rochford, assistant professor of epidemiology, is the U-M spokesperson on FluMist.
MedImmune planned a webcast at 5:30 p.m. July 11 to discuss the FDA’sresponse to its biologics license application for FluMist. The site ishttp://www.medimmune.com. A replay of the webcast will be available viaMedImmune’s website until midnight July 18.A MedImmune press release on the FDA’s response isavailable at http://investor.medimmune.com/news/20020711-84556.cfm?ReleaseID=84556 --
Maassab finished his doctoral dissertation on influenza in 1956, inspired by his mentor, Dr. Thomas Francis Jr., who had overseen the U.S. Army's flu vaccine program during World War II. Francis was founder of U-M's epidemiology department and a mentor to Jonas Salk; he oversaw the polio vaccine clinical trials conducted at U-M.
Maassab maintained his interest in flu, building on one finding after another before ultimately coming to the approach used in FluMist, a cold-adapted, live-attenuated, trivalent influenza virus vaccine.
Unlike traditional flu shots, which are made from killed viruses, FluMist is designed with weakened live viruses that are modified to grow in the cooler nasal passages but not in the warmer lungs, where flu develops. It helps the recipient develop immunity at the site where the flu virus typically enters the body, the nose. Trivalent means it would include three strains of the flu virus because multiple strains of influenza virus circulate in the population every year. The immune response is different to each of these strains so an effective vaccine gives protection against each.
According to the Centers for Disease Control and Prevention, millions of Americans get the flu each year. An average of about 20,000 people in the United States die from the flu annually, and 114,000 per year are admitted to the hospital because of flu.For more information: http://www.cdc.gov/ncidod/diseases/flu/fluinfo.htm
For background on Maassab’s work on influenza at Michigan, including a timeline of his research and biographical information: http://www.sph.umich.edu/news_events/flumist/This site also includes information on U-M’s Technology Transfer Office, past media coverage, a list of related web sites, and photos of Maassab.
In January, MedImmune acquired Aviron, which previously held the license for FluMist. For more on that merger, visit the MedImmune web site news section: http://investor.medimmune.com/news/20011203-66085.cfm
Story Source:
Materials provided by University Of Michigan. Note: Content may be edited for style and length.
Cite This Page: